What are the indications, dosing regimens, contraindications, adverse effects, monitoring parameters, and alternative therapies for bisoprolol hemifumarate (bisoprolol fumarate)?

Bisoprolol Hemifumarate (Bisoprolol Fumarate)

Primary Indications

Bisoprolol is indicated for hypertension and heart failure with reduced ejection fraction (HFrEF), with the strongest evidence supporting its use in HFrEF where it reduces all-cause mortality by 34%. 1, 2

Heart Failure with Reduced Ejection Fraction (HFrEF)

• Bisoprolol is one of only three beta-blockers proven to reduce mortality in HFrEF (the others being carvedilol and metoprolol succinate extended-release) 1, 3, 4
• Indicated for all stable patients with current or prior symptoms of HFrEF, regardless of NYHA functional class 1, 4
• Must be added to background therapy with diuretics and ACE inhibitors/ARBs 1, 4
• Reduces hospitalizations, improves functional class, and prevents worsening heart failure 1

Hypertension

• Effective for blood pressure control when administered once daily 5, 6, 7
• Not recommended as first-line therapy unless patient has coexisting ischemic heart disease or heart failure 3

Chronic Stable Angina Pectoris

• Reduces frequency of angina attacks; 56% of patients become angina-free 8
• Effective antianginal agent with once-daily dosing 8

---

Dosing Regimens

Heart Failure with Reduced Ejection Fraction

Starting dose: 1.25 mg once daily 1, 3

Target dose: 10 mg once daily 1, 3

Titration schedule: Double the dose every 2 weeks if tolerated, progressing through 1.25 mg → 2.5 mg → 3.75 mg → 5 mg → 7.5 mg → 10 mg 1, 3, 4

• Approximately 85% of patients can reach target doses with cautious titration 4
• If target dose cannot be achieved, aim for at least 50% of target (5 mg daily minimum) as dose-response relationships exist for mortality benefit 3
• Even lower doses provide benefit if target doses cannot be tolerated 3

Hypertension

Starting dose: 2.5 mg once daily 3

Target dose: 10 mg once daily 3

Maximum dose: 20 mg once daily, though doses above 10 mg provide limited additional benefit 3, 6

• The 20 mg dosage regimen is more effective than 5 mg or 10 mg for blood pressure control 6

---

Contraindications

Absolute Contraindications

• Current or recent (within 4 weeks) decompensated heart failure requiring hospitalization 1, 3, 4
• Need for intravenous inotropic therapy 4
• Second- or third-degree atrioventricular block without a permanent pacemaker 1, 3, 4
• Sick sinus syndrome without a permanent pacemaker 3
• Sinus bradycardia <50 beats/min 3
• Active asthma with persistent symptoms 3, 4
• Symptomatic hypotension 4

Relative Contraindications

• Reactive airway disease or asymptomatic bradycardia (may be used with close monitoring) 4
• Peripheral atherosclerosis (use with caution) 5

---

Adverse Effects

Common Adverse Effects (≥1% incidence) 9

Cardiovascular: Bradycardia (0.4%), palpitations, cold extremities, claudication, hypotension, orthostatic hypotension, chest pain 9

Central Nervous System: Dizziness (3.8%), headache (11.4%), hypoesthesia (0.8%), vertigo, syncope, paresthesia, somnolence, decreased concentration/memory 9

Gastrointestinal: Diarrhea (1.5%), nausea (1.5%), vomiting (1.1%), gastric/epigastric pain, dyspepsia, constipation 9

Respiratory: Pharyngitis (2.3%), rhinitis (3.0%), sinusitis (1.5%), upper respiratory infection (3.8%), cough (4.5%), dyspnea (1.1%) 9

Musculoskeletal: Arthralgia (2.3%), muscle/joint pain, back/neck pain, muscle cramps 9

Psychiatric: Insomnia (2.3%), vivid dreams, depression (0.8%), anxiety/restlessness 9

General: Fatigue (1.5%), asthenia, chest pain, peripheral edema (3.8%), malaise 9

Skin: Increased sweating (1.5%), rash, pruritus, flushing 9

Genitourinary: Decreased libido/impotence, Peyronie's disease 9

Dose-Related Adverse Effects

• Bradycardia, diarrhea, asthenia, fatigue, and sinusitis appear to be dose-related 9

Serious Adverse Effects

• Angioedema (rare, <1%) 9
• Bronchospasm 9
• Congestive heart failure 9
• Reversible mental depression progressing to catatonia 9
• Agranulocytosis, thrombocytopenia (rare) 9

Laboratory Abnormalities

• Most frequently reported: increase in serum triglycerides (not consistent) 9
• Sporadic liver test abnormalities 9
• Concomitant elevations in SGOT and SGPT (1-2 times normal) occurred in 3.9% of patients 9

Withdrawal Rate

• Withdrawal for adverse events: 3.3% (compared to 6.8% for placebo) 9
• Withdrawals for bradycardia or fatigue/lack of energy: <1% 9

---

Monitoring Parameters

During Initiation and Titration (every 1-2 weeks) 3, 4

• Heart rate (target >50 bpm) 3, 4
• Blood pressure (monitor for symptomatic hypotension) 3, 4
• Clinical status, especially signs of congestion 3, 4
• Body weight (patients should weigh themselves daily) 3, 4
• Signs of worsening heart failure (dyspnea, fatigue, edema) 3

Long-Term Monitoring

• Blood chemistry at 12 weeks after initiation and 12 weeks after final dose titration 3
• Renal function and electrolytes (especially potassium) 3
• Liver function tests (sporadic abnormalities reported) 9

Patient Self-Monitoring

• Daily weights: increase diuretic dose if weight increases by 1.5-2.0 kg over 2 consecutive days 3, 4

---

Management of Adverse Reactions

Worsening Congestion or Fluid Retention

1. First: Double the diuretic dose 3, 4
2. Second: Halve the bisoprolol dose only if increasing diuretic fails 3, 4
3. Never permanently discontinue 3, 4

Marked Fatigue

• Halve the bisoprolol dose 3, 4

Symptomatic Bradycardia (<50 bpm with worsening symptoms)

• Halve the dose 3, 4
• Seek specialist input if severe deterioration occurs 4

Symptomatic Hypotension

1. First: Reduce or eliminate nitrates, calcium-channel blockers, and other vasodilators 3, 4
2. Second: Reduce diuretic dose if no signs of congestion 3, 4
3. Third: Halve the bisoprolol dose only if above measures fail 3, 4
4. Last resort: Seek specialist advice; discontinuation should be rare 3

Critical Safety Warning

Never abruptly discontinue bisoprolol due to risk of rebound myocardial ischemia, infarction, and ventricular arrhythmias 3, 4

• If discontinuation is absolutely necessary, taper gradually over approximately one week under close surveillance 3
• Reduce dose by 25-50% every 7 days 3
• Exercise extreme caution in patients with coronary artery disease 3

---

Alternative Therapies

For Heart Failure with Reduced Ejection Fraction

Other Evidence-Based Beta-Blockers:

• Carvedilol: 3.125 mg twice daily, titrate to 25-50 mg twice daily 1, 3
  • Provides combined alpha-1 and beta-blockade with additional vasodilation 3
• Metoprolol succinate extended-release: 12.5-25 mg once daily, titrate to 200 mg once daily 1, 3
  • Critical: Only metoprolol succinate (not tartrate) has proven mortality benefit 3, 4

When to Consider Alternatives:

• If bisoprolol causes intolerable side effects despite dose adjustment 3
• If patient has difficulty with once-daily dosing compliance 3
• Seek specialist advice before permanently stopping bisoprolol 3

For Hypertension (if beta-blocker not appropriate)

• ACE inhibitors, ARBs, calcium-channel blockers, or thiazide diuretics as first-line agents 3
• Beta-blockers not recommended as first-line unless coexisting ischemic heart disease or heart failure 3

---

Special Populations and Clinical Pearls

Patients with Bronchospastic Disease

• Bisoprolol is cardioselective (beta-1 selective) and may be used cautiously in patients with bronchospastic airway disease 3, 7
• Use lowest effective dose with readily available bronchodilators 10

Patients with Diabetes

• Minimal effects on glucose tolerance 7
• Well tolerated in patients with diabetes 5

Patients with Peripheral Atherosclerosis

• Can be used with appropriate monitoring 5

Elderly Patients

• Good tolerability confirmed in elderly populations 2

Patients with Left Bundle Branch Block

• LBBB is not a contraindication to bisoprolol therapy 10
• Monitor heart rate and blood pressure closely during titration 10

Common Pitfalls

• Underdosing: Fewer than 25% of patients in real-world settings are titrated to target doses, compared to 64% in clinical trials 3
• Premature discontinuation: Some beta-blocker is better than no beta-blocker when target doses cannot be achieved 3, 4
• Abrupt cessation: Can lead to rebound hypertension or worsening ischemia 3

Drug Interactions

• No clinically important drug interactions reported at therapeutic doses 7
• Avoid combining with other negative chronotropic or inotropic agents without careful monitoring 4

---

Pharmacokinetic Considerations

• Highly selective beta-1 receptor blocker 2, 7
• Plasma half-life: 10-12 hours, allowing once-daily dosing 6, 7
• No intrinsic sympathomimetic activity 2, 7
• No membrane-stabilizing effects at therapeutic doses 2, 7
• Minimal effects on plasma lipid profiles 7